$GILD Recent Headlines 10 stocks enjoying the biggest

New Post Public Reply Private Reply Replies (0) Message Board

Aug 13, 2014 at 10:31 AM

$GILD Recent Headlines

10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney
Gilead's moment of truth arrives: How does Sovaldi impact earnings? 1:18 p.m. July 23, 2014 - blogs.marketwatch.com

Gilead (GILD) Hits New Lifetime High Today 42 min ago - TheStreet.com
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape 8:30 a.m. Today - Zacks.com
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day 3:06 a.m. Today - Zacks.com
Apple, Facebook Among 5 Top Rated Big Cap Stocks 7:18 p.m. Aug. 12, 2014 - Investors Business Daily
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog 5:20 p.m. Aug. 12, 2014 - Zacks.com
Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog 4:20 p.m. Aug. 12, 2014 - Zacks.com
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog 2:49 p.m. Aug. 12, 2014 - Zacks.com
Gilead Sciences Looks Like A Contrarian Short 12:51 p.m. Aug. 12, 2014 - Seeking Alpha
Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential 12:27 p.m. Aug. 12, 2014 - Seeking Alpha
Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog 11:30 a.m. Aug. 12, 2014 - Zacks.com
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog 11:05 a.m. Aug. 12, 2014 - Zacks.com
Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised - Analyst Blog 10:38 a.m. Aug. 12, 2014 - Zacks.com
Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus - Analyst Blog 9:58 a.m. Aug. 12, 2014 - Zacks.com
Intercept Pharma Soars On Liver-Disease Drug Data 9:48 a.m. Aug. 12, 2014 - Investors Business Daily
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape 9:39 a.m. Aug. 12, 2014 - Zacks.com
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape 8:51 a.m. Aug. 12, 2014 - Zacks.com
Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential - Tale of the Tape 8:29 a.m. Aug. 12, 2014 - Zacks.com
'Mad Money' Lightning Round: I'm Not Crazy About El Pollo Loco 6:00 a.m. Aug. 12, 2014 - TheStreet.com
Cramer's Lightning Round - El Pollo Loco Is Acting Crazy (8/11/14) 5:44 a.m. Aug. 12, 2014 - Seeking Alpha
What is Your Stock's Earnings Yield? - Screen of the Week 3:17 a.m. Aug. 12, 2014 - Zacks.com

Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fermaca and NVIDIA Join Forces for AI Revolution

When you think about AI these days, visions of sleek robots and endless data streams might crowd the brain. What Fermaca's teasing out in Mexico, though, ain't no sci-fi dream. They're yanking AI tech out of the clouds and plugging it straight into the ground, partnering with NVIDIA to make it happen. A Fresh Model on Familiar Grounds Fermaca, now rocking the badge of...

Illinois House Democrats Surge with Historic Gaines

Turning the Election Tide in Illinois Damn, if you're not paying attention to what's shaking in Illinois, it's time to listen up. The Democrats under Speaker Emanuel "Chris" Welch are strutting their stuff, leaving an indelible mark on the political landscape. An eye-popping $35 million in campaign dough was raised, safeguarding every Democratic incumbent and managing to...

Saga Metals Advances Radar Project with HQ Drill Success

Digging Deep at Trapper North: Saga's Strategic Drill Move There's nothing like the thrill of discovery, especially in the rough-and-tumble world of mining exploration. Saga Metals Corp., anchored deep in the critical minerals scene, has wrapped up an HQ-diameter drill program at its Radar Project, smack dab near Cartwright, Labrador. You hear 1,010 meters and maybe...

Webull's Legal Woes: Shareholder Class Action Heats Up

Webull's Legal Storm: What's Behind the Class Action? Here's a tale as old as time in the wild world of the stock market: a company paints a rosy picture, investors follow the trail, and when the curtain lifts, the scenery looks starkly different. Enter Webull Corporation (NASDAQ: BULL), caught in the thick of allegations that have turned the investor community's...

Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

New Story Appoints Drudge, Celebrates Workplace Recognition

A Dual Milestone: Leadership and Recognition In an industry chock-full of buzzwords, New Story’s latest moves cut through the noise. They've just announced Adam Drudge as their new Chief People Officer, and wouldn't you know it, they've snagged their third straight Most Loved Workplace® recognition for 2026. When a special ed company starts making waves like this,...

Cerillion 26.2: New AI Powers & Open Standards Edge

Leading the Charge in Telecom AI Ah, the telecom game—it's a battlefield and Cerillion’s just lobbed a game-changer onto the field with their 26.2 release. This ain’t your run-of-the-mill update; we're talking expanded agentic AI capabilities that are set to shake the very core of BSS/OSS solutions. AI Innovations That Matter No fluff here, just solid improvements....

Systemair Wins First Natural Refrigerant Heat Pump Deal

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...

Stellus Capital Set to Unveil Q3 Results: Key Details

Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...

LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...